Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Edirol’s Tablet Forms Approved in Japan, Towa Responsible for Distribution
Chugai Pharmaceutical on August 15 received Japanese regulatory approval for tablet versions of its osteoporosis treatment Edirol (eldecalcitol), which has been available only in soft capsule forms.The new versions, which are slated to be launched upon NHI pricing listing in…
To read the full story
Related Article
- Chugai, Towa Release Edirol’s Tablet Form in Japan
December 12, 2022
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- BIKEN to Take Full Control of Vaccine JV with Tanabe Pharma
April 2, 2026
- Yoshindo Eyes Biosimilar API Production from 2028 with Cytiva Support
April 2, 2026
- Nippon Kayaku to Buy Fuji Yakuhin’s Injectable Plant in Japan
April 2, 2026
- Teijin Slashes FY2025 Forecast on Pharma Impairment
April 2, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…